WallStreetZenWallStreetZen

NASDAQ: ZVRA
Zevra Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for ZVRA

Based on 4 analysts offering 12 month price targets for Zevra Therapeutics Inc.
Min Forecast
$10.00+102.02%
Avg Forecast
$15.50+213.13%
Max Forecast
$20.00+304.04%

Should I buy or sell ZVRA stock?

Based on 4 analysts offering ratings for Zevra Therapeutics Inc.
Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ZVRA stock forecasts and price targets.

ZVRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Maxim Group
Bottom 2%
2
Strong BuyInitiates Coverage On$12.00+142.42%2023-03-17
Cantor Fitzgerald
Bottom 32%
32
Strong BuyInitiates Coverage On$20.00+304.04%2022-11-17
Canaccord Genuity
Bottom 13%
13
Strong BuyInitiates Coverage On$20.00+304.04%2022-09-15
HC Wainwright & Co.
Bottom 5%
5
BuyMaintains$10.00+102.02%2022-08-17

1 of 1

Forecast return on equity

Is ZVRA forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is ZVRA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

ZVRA earnings per share forecast

What is ZVRA's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.57
Avg 2 year Forecast
$0.03
Avg 3 year Forecast
$0.16

ZVRA revenue forecast

What is ZVRA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$24.2M+131.41%
Avg 2 year Forecast
$38.9M+271.58%
Avg 3 year Forecast
$32.6M+211.24%
ZVRA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ZVRA revenue growth forecast

How is ZVRA forecast to perform vs Biotechnology companies and vs the US market?
Company
51.5%
Industry
40.95%
Market
8.76%
ZVRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ZVRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ZVRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ZVRA$4.95$15.50+213.13%Strong Buy
ADCT$2.10$9.80+366.67%Buy
RLYB$4.55$25.00+449.45%Strong Buy
IVVD$1.54$2.00+29.87%Strong Sell
TNYA$2.61$19.00+627.97%Strong Buy

Zevra Therapeutics Stock Forecast FAQ

Is Zevra Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ZVRA) stock is to Strong Buy ZVRA stock.

Out of 4 analysts, 3 (75%) are recommending ZVRA as a Strong Buy, 1 (25%) are recommending ZVRA as a Buy, 0 (0%) are recommending ZVRA as a Hold, 0 (0%) are recommending ZVRA as a Sell, and 0 (0%) are recommending ZVRA as a Strong Sell.

If you're new to stock investing, here's how to buy Zevra Therapeutics stock.

What is ZVRA's earnings growth forecast for 2023-2025?

(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Zevra Therapeutics's earnings in 2023 is -$41,543,000.On average, 2 Wall Street analysts forecast ZVRA's earnings for 2023 to be -$19,688,036, with the lowest ZVRA earnings forecast at -$29,704,756, and the highest ZVRA earnings forecast at -$10,016,720. On average, 1 Wall Street analyst forecast ZVRA's earnings for 2024 to be $1,036,212, with the lowest ZVRA earnings forecast at $1,036,212, and the highest ZVRA earnings forecast at $1,036,212.

In 2025, ZVRA is forecast to generate $5,526,466 in earnings, with the lowest earnings forecast at $5,526,466 and the highest earnings forecast at $5,526,466.

What is ZVRA's revenue growth forecast for 2023-2025?

(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 51.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Zevra Therapeutics's revenue in 2023 is $10,458,000.On average, 2 Wall Street analysts forecast ZVRA's revenue for 2023 to be $835,912,559, with the lowest ZVRA revenue forecast at $550,643,280, and the highest ZVRA revenue forecast at $1,121,181,838. On average, 1 Wall Street analysts forecast ZVRA's revenue for 2024 to be $1,342,240,488, with the lowest ZVRA revenue forecast at $1,342,240,488, and the highest ZVRA revenue forecast at $1,342,240,488.

In 2025, ZVRA is forecast to generate $1,124,290,476 in revenue, with the lowest revenue forecast at $1,124,290,476 and the highest revenue forecast at $1,124,290,476.

What is ZVRA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: ZVRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is ZVRA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ZVRA price target, the average ZVRA price target is $15.50, with the highest ZVRA stock price forecast at $20.00 and the lowest ZVRA stock price forecast at $10.00.

On average, Wall Street analysts predict that Zevra Therapeutics's share price could reach $15.50 by Mar 17, 2024. The average Zevra Therapeutics stock price prediction forecasts a potential upside of 213.13% from the current ZVRA share price of $4.95.

What is ZVRA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: ZVRA) Zevra Therapeutics's current Earnings Per Share (EPS) is -$1.20. On average, analysts forecast that ZVRA's EPS will be -$0.57 for 2023, with the lowest EPS forecast at -$0.86, and the highest EPS forecast at -$0.29. On average, analysts forecast that ZVRA's EPS will be $0.03 for 2024, with the lowest EPS forecast at $0.03, and the highest EPS forecast at $0.03. In 2025, ZVRA's EPS is forecast to hit $0.16 (min: $0.16, max: $0.16).

What is ZVRA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: ZVRA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.